Tregalizumab
Oral Lichen Planus (oLP)
Key Facts
About CD4 Therapeutics
CD4 Therapeutics is a private, clinical-stage biotech pioneering Treg-activating therapies, with Tregalizumab as its lead candidate. The company secured exclusive worldwide rights to Tregalizumab in July 2024 and is targeting fast-track development in high-need, orphan-designation indications. With a lean strategy, strong IP, and a leadership team boasting decades of industry experience, CD4 positions itself as a de-risked investment opportunity in the rapidly expanding autoimmune therapeutics market.
View full company profileAbout CD4 Therapeutics
CD4 Therapeutics is a private, clinical-stage biotech pioneering Treg-activating therapies, with Tregalizumab as its lead candidate. The company secured exclusive worldwide rights to Tregalizumab in July 2024 and is targeting fast-track development in high-need, orphan-designation indications. With a lean strategy, strong IP, and a leadership team boasting decades of industry experience, CD4 positions itself as a de-risked investment opportunity in the rapidly expanding autoimmune therapeutics market.
View full company profileTherapeutic Areas
Other Oral Lichen Planus (oLP) Drugs
| Drug | Company | Phase |
|---|---|---|
| LP-10 (Oral Rinse) | Lipella Pharmaceuticals | Phase 2a |